Chronic Kidney Disease

Remote BP monitoring and collaborative telehealth visits with a pharmacist improved BP control among patients at rural nephrology clinics and reduced hospitalization, a speaker reported.

DaVita has appointed David Maughan as its new chief operating officer, according to a company press release.

In patients with obesity and heart disease, semaglutide 2.4 mg reduced risk for major adverse cardiovascular events regardless of baseline kidney function, according to new data from the SELECT trial.

Level of kidney function, rate of decline and type of renal disease are key factors influencing the decision to initiate kidney replacement therapy, whether dialysis or transplantation, for pediatric patients, according to study data. 

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone improved outcomes compared with placebo regardless of baseline diabetes status, according to new data from the FINEARTS-HF trial.

As Akebia Therapeutics announced plans to launch its anemia drug Vafseo to the dialysis community, company officials said they intend to work with the FDA for more testing of the drug for the pre-dialysis market.

A clinical scale was validated for early detection of infections at the exit site of central venous catheters for hemodialysis in patients with kidney disease, according to a study.

The National Kidney Foundation launched a new interactive portal that lets patients with chronic kidney disease learn more about their condition, according to a press release.

Canagliflozin may reduce albuminuria and patient-specific eGFR decline in patients with type 2 diabetes and microalbuminuria, researchers found in a parallel, open-labeled trial.

Adults with chronic kidney disease managed with hemodiafiltration reported less drop in health-related of quality of life, particularly in cognitive decline, compared with those using hemodialysis, according to data from the CONVINCE trial.